These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22681671)

  • 1. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.
    Khandani AH; Rathmell WK
    Semin Nucl Med; 2012 Jul; 42(4):221-30. PubMed ID: 22681671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
    Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
    Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
    Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
    Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of
    Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.
    Urso L; Castello A; Rocca GC; Lancia F; Panareo S; Cittanti C; Uccelli L; Florimonte L; Castellani M; Ippolito C; Frassoldati A; Bartolomei M
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1299-1311. PubMed ID: 35217902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis.
    Ma H; Shen G; Liu B; Yang Y; Ren P; Kuang A
    Nucl Med Commun; 2017 Feb; 38(2):156-163. PubMed ID: 27824726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.
    Gilles R; de Geus-Oei LF; Mulders PF; Oyen WJ
    World J Urol; 2013 Aug; 31(4):841-6. PubMed ID: 21739122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
    Harrison MR; George DJ
    Clin Cancer Res; 2011 Sep; 17(18):5841-3. PubMed ID: 21926167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
    Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
    Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.
    Mizuno T; Kamai T; Abe H; Sakamoto S; Kitajima K; Nishihara D; Yuki H; Kambara T; Betsunoh H; Yashi M; Fukabori Y; Kaji Y; Yoshida K
    BMC Cancer; 2015; 15():1097. PubMed ID: 25784113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma.
    Ozturk H
    Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.